Loss of efficacy of biologic therapies in psoriatic patients is a well known event. Currently only few data are available on switching from Secukinumab to other biologic therapies. In our study we extended the follow-up at 24 weeks showing that Ixekizumab might represent a valid and safe treatment option in psoriatic patients who failed Secukinumab.
Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience / Conti A.; Peccerillo F.; Amerio P.; Balato A.; Bardazzi F.; Bianchi L.; Burlando M.; Cannavo S.P.; Chiricozzi A.; Dapavo P.; De Simone C.; Fargnoli M.C.; Gambardella A.; Gisondi P.; Malagoli P.; Malara G.; Mugheddu C.; Offidani A.M.; Piaserico S.; Prignano F.; Stingeni L.; Pellacani G.. - In: BRITISH JOURNAL OF DERMATOLOGY. - ISSN 0007-0963. - STAMPA. - 180:(2019), pp. 1547-1548. [10.1111/bjd.17580]
Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience
Prignano F.;
2019
Abstract
Loss of efficacy of biologic therapies in psoriatic patients is a well known event. Currently only few data are available on switching from Secukinumab to other biologic therapies. In our study we extended the follow-up at 24 weeks showing that Ixekizumab might represent a valid and safe treatment option in psoriatic patients who failed Secukinumab.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
